HK1211475A1 - Combination therapy - Google Patents

Combination therapy

Info

Publication number
HK1211475A1
HK1211475A1 HK15112282.5A HK15112282A HK1211475A1 HK 1211475 A1 HK1211475 A1 HK 1211475A1 HK 15112282 A HK15112282 A HK 15112282A HK 1211475 A1 HK1211475 A1 HK 1211475A1
Authority
HK
Hong Kong
Prior art keywords
combination therapy
therapy
combination
Prior art date
Application number
HK15112282.5A
Other languages
English (en)
Chinese (zh)
Inventor
Shivang Doshi
Sunkyu Kim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1211475A1 publication Critical patent/HK1211475A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15112282.5A 2012-11-28 2015-12-14 Combination therapy HK1211475A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730661P 2012-11-28 2012-11-28
PCT/US2013/071659 WO2014085318A1 (en) 2012-11-28 2013-11-25 Combination therapy

Publications (1)

Publication Number Publication Date
HK1211475A1 true HK1211475A1 (en) 2016-05-27

Family

ID=49753505

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112282.5A HK1211475A1 (en) 2012-11-28 2015-12-14 Combination therapy

Country Status (12)

Country Link
US (1) US9408847B2 (de)
EP (1) EP2925365A1 (de)
JP (2) JP2016501221A (de)
KR (1) KR20150089053A (de)
CN (1) CN104812414A (de)
AU (4) AU2013352406A1 (de)
BR (1) BR112015012197A8 (de)
CA (1) CA2891938A1 (de)
HK (1) HK1211475A1 (de)
MX (1) MX2015006809A (de)
RU (1) RU2015125307A (de)
WO (1) WO2014085318A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359406B (es) * 2011-07-01 2018-09-27 Novartis Ag Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3kpara usarse en el tratamiento de cáncer.
CA2906166C (en) 2013-03-15 2023-03-14 G1 Therapeutics, Inc. Hspc-sparing treatments for rb-positive abnormal cellular proliferation
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
CA2943611A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
WO2016040892A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies
EP3200775B1 (de) 2014-10-03 2019-11-20 Novartis AG Kombinationstherapien
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
CN106336412A (zh) * 2015-07-10 2017-01-18 南开大学 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
EP3964528A1 (de) 2015-07-29 2022-03-09 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen lag-3
EP3878465A1 (de) 2015-07-29 2021-09-15 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen tim-3
EP3156406A1 (de) * 2015-10-14 2017-04-19 ratiopharm GmbH Kristalline formen von ribociclib freie base
AU2016348391A1 (en) 2015-11-03 2018-05-17 Janssen Biotech, Inc. Antibodies specifically binding TIM-3 and their uses
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
SG11201811225RA (en) * 2016-06-22 2019-01-30 Radius Health Inc Ar+ breast cancer treatment methods
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
EP4218820A3 (de) 2017-03-16 2023-09-20 Eisai R&D Management Co., Ltd. Kombinationstherapien zur behandlung von brustkrebs
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
EP3642240A1 (de) 2017-06-22 2020-04-29 Novartis AG Antikörpermoleküle gegen cd73 und verwendungen davon
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2020103922A1 (en) * 2018-11-23 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Novel pharmaceutical composition and use thereof
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2558092B1 (de) * 2010-04-13 2018-06-27 Novartis AG Kombination mit einem hemmer der cyclin-abhängigen kinase-4 oder cyclinabhängigen kinase-6 (cdk4/6) und everolimus zur behandlung von krebs

Also Published As

Publication number Publication date
AU2016262781A1 (en) 2016-12-15
CA2891938A1 (en) 2014-06-05
RU2015125307A (ru) 2017-01-10
JP2016501221A (ja) 2016-01-18
US9408847B2 (en) 2016-08-09
AU2019200881A1 (en) 2019-02-28
CN104812414A (zh) 2015-07-29
EP2925365A1 (de) 2015-10-07
JP2019031500A (ja) 2019-02-28
AU2013352406A1 (en) 2015-06-04
US20150306104A1 (en) 2015-10-29
WO2014085318A1 (en) 2014-06-05
BR112015012197A8 (pt) 2019-10-01
BR112015012197A2 (pt) 2017-07-11
MX2015006809A (es) 2015-08-06
KR20150089053A (ko) 2015-08-04
AU2018200323A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
HK1211475A1 (en) Combination therapy
HK1203963A1 (en) Novel therapeutic agents
ZA201305897B (en) Combination therapy
GB201212513D0 (en) Therapeutic agents
EP2934531A4 (de) Kombination
PL2854944T3 (pl) Urządzenia do fototerapii
ZA201400120B (en) Combination therapy
GB201217439D0 (en) Combination therapy
EP2911673A4 (de) Kombination
GB201217704D0 (en) Therapeutic agents
GB201207305D0 (en) Therapy
EP2701744A4 (de) Kombinationstherapie
HK1210426A1 (en) Combination therapy
IL238174A0 (en) Combined treatment with Valasertiv
EP2804853A4 (de) Therapeutische verwendungen
EP2925728A4 (de) Kombination
GB201211543D0 (en) Combination therapy
IL236873A0 (en) therapeutic compounds
ZA201405764B (en) Novel therapeutic agents
GB201223021D0 (en) Therapeutic agents
EP2908815A4 (de) Kombination
EP2908816A4 (de) Kombination
GB201212512D0 (en) Therapeutic agents
GB201210233D0 (en) Therapeutic agents
GB201211135D0 (en) Treatment